Frequently asked questions

The program is designed for startups and SMEs developing innovative solutions in biotech, MedTech, wound care, regenerative medicine, and related life-science fields, with a strong focus on commercialization and scalability.

We primarily target startups with a validated concept, MVP, prototype, or early market traction. Teams with strong scientific validation and clear commercialization potential are encouraged to apply.

Yes. Startups must be legally registered entities at the time of program start. Teams in the final stages of incorporation may apply but must complete registration before onboarding.

No. Investment is not guaranteed. Investment discussions are conducted separately from the accelerator program and depend on strategic fit, performance, and mutual interest.

Startups receive structured mentoring, expert-led workshops, commercialization guidance, regulatory and IP insights, fundraising preparation, and access to EmeraNova’s network and infrastructure.

Mentors include experienced industry professionals, researchers, clinicians, regulatory experts, investors, and business development specialists.

Mentoring is provided through a mix of 1:1 sessions, group workshops, expert clinics, and tailored advisory support, depending on the startup’s needs and maturity level.

The program is primarily delivered online, with selected in-person sessions, demo days, or partner meetings where relevant and feasible.

Founders should expect to dedicate approximately 4–6 hours per week, including workshops, mentoring sessions, and independent work on assigned milestones.

All startups receive post-program support, including investor introductions, alumni network membership, and strategic guidance for scaling and fundraising.

Yes. All participants sign NDAs where appropriate. Startups retain full ownership of their intellectual property unless otherwise agreed in a separate, written contract.

No, there is no application fee to apply to the accelerator.

Startups are evaluated based on innovation level, scientific and technical strength, market potential, team capability, and strategic fit with the program and partners.

Yes, as long as there are no exclusivity conflicts and participation does not violate existing agreements.

The program uniquely bridges startups directly with EmeraNova, combining scientific depth, real industrial validation, and a strong pathway toward strategic partnerships and investment.